Enterprise Value
-67.15M
Cash
246.5M
Avg Qtr Burn
-31.48M
Short % of Float
23.24%
Insider Ownership
49.35%
Institutional Own.
35.14%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Posoleucel Details Human herpesvirus 6, Epstein-Barr virus, Adenovirus, BK virus, Cytomegalovirus | Phase 3 Data readout | |
Posoleucel Details Virus-associated hemorrhagic cystitis , Adenovirus | Phase 3 Data readout | |
Posoleucel Details BK virus, Kidney transplantation | Phase 2 Update | |
ALVR106 Details Parainfluenza virus, Human metapneumovirus, Respiratory syncytial virus, Influenza | Phase 1/2 Interim update | |
ALVR109 Details COVID-19 | Failed Discontinued |